- Home
- USCB vs NYXH Comparison
USCB vs NYXH Comparison
Compare USCB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- NYXH
- Stock Information
- Founded
- USCB 2002
- NYXH 2009
- Country
- USCB United States
- NYXH Belgium
- Employees
- USCB N/A
- NYXH N/A
- Industry
- USCB Major Banks
- NYXH Medical/Dental Instruments
- Sector
- USCB Finance
- NYXH Health Care
- Exchange
- USCB Nasdaq
- NYXH Nasdaq
- Market Cap
- USCB 353.0M
- NYXH 394.1M
- IPO Year
- USCB 2021
- NYXH 2021
- Fundamental
- Price
- USCB $18.95
- NYXH $10.35
- Analyst Decision
- USCB Buy
- NYXH Strong Buy
- Analyst Count
- USCB 2
- NYXH 5
- Target Price
- USCB $18.25
- NYXH $17.00
- AVG Volume (30 Days)
- USCB 19.9K
- NYXH 30.7K
- Earning Date
- USCB 01-23-2025
- NYXH 03-13-2025
- Dividend Yield
- USCB 1.32%
- NYXH N/A
- EPS Growth
- USCB 47.62
- NYXH N/A
- EPS
- USCB 1.24
- NYXH N/A
- Revenue
- USCB $79,519,000.00
- NYXH $5,668,079.00
- Revenue This Year
- USCB N/A
- NYXH $22.93
- Revenue Next Year
- USCB $7.69
- NYXH $411.04
- P/E Ratio
- USCB $15.28
- NYXH N/A
- Revenue Growth
- USCB 25.02
- NYXH 32.65
- 52 Week Low
- USCB $10.25
- NYXH $6.76
- 52 Week High
- USCB $21.86
- NYXH $20.00
- Technical
- Relative Strength Index (RSI)
- USCB 49.36
- NYXH 51.74
- Support Level
- USCB $18.86
- NYXH $10.47
- Resistance Level
- USCB $19.41
- NYXH $10.92
- Average True Range (ATR)
- USCB 0.70
- NYXH 0.41
- MACD
- USCB -0.09
- NYXH -0.11
- Stochastic Oscillator
- USCB 23.28
- NYXH 4.61
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.